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Abstract:  The  only  curative  treatment  for  hepatic  failure  is  liver  transplantation. 
Unfortunately, this treatment has several major limitations, as for example donor organ 
shortage. A previous report demonstrated that transplantation of induced pluripotent stem 
cells  without  reprogramming  factor  c-Myc  (3-genes  iPSCs)  attenuates  thioacetamide-
induced  hepatic  failure  with  minimal  incidence  of  tumorigenicity.  In  this  study,  we 
investigated  whether  3-genes  iPSC  transplantation  is  capable  of  rescuing  carbon 
tetrachloride (CCl4)-induced fulminant hepatic failure and hepatic encephalopathy in mice. 
Firstly,  we  demonstrated  that  3-genes  iPSCs  possess  the  capacity  to  differentiate  into 
hepatocyte-like  cells  (iPSC-Heps)  that  exhibit  biological  functions  and  express  various 
hepatic specific markers. 3-genes iPSCs also exhibited several antioxidant enzymes that 
prevented CCl4-induced reactive oxygen species production and cell death. Intraperitoneal 
transplantation  of  either  3-genes  iPSCs  or  3-genes  iPSC-Heps  significantly  reduced  
hepatic necrotic areas, improved hepatic functions, and survival rate in CCl4-treated mice.  
CCl4-induced hepatic encephalopathy was also improved by 3-genes iPSC transplantation. 
Hoechst staining confirmed the successful engraftment of both 3-genes iPSCs and 3-genes 
iPSC-Heps,  indicating  the  homing  properties  of  these  cells.  The  most  pronounced 
hepatoprotective effect of iPSCs appeared to originate from the highest antioxidant activity 
of 3-gene iPSCs among all transplanted cells. In summary, our findings demonstrated that 
3-genes iPSCs serve as an available cell source for the treatment of an experimental model 
of acute liver diseases. 




Acute hepatic failure (AHF) is a severe liver injury accompanied by sustained liver damage and 
complications  including  increased  blood  levels  of  hepatic  enzymes  and  hepatic  encephalopathy. 
Management of severe AHF is one of the most challenging problems in clinical medicine [1]. Liver 
transplantation has been shown to be the only curative treatment for hepatic failure. Unfortunately, 
several major  limitations of this  treatment  exist, such as  donor organ shortage  and high  cost  [2].  
Cell-based therapy has been implicated in the treatment of liver diseases. For example, embryonic stem 
cells (ESCs) can differentiate into functional hepatocytes that effectively replace injured parenchyma [3].  
Without the ESC-related disadvantages, which include ethical issues and immunorejection, induced 
pluripotent stem cell (iPSC) is an alternative potential cell source for cell-based therapy against liver 
diseases. iPSCs can be generated from mouse or human fibroblasts using retroviral transfection of four 
transcription  factors  (Oct4/Sox2/Klf4/c-Myc)  [4–6],  and  similarly,  these  4-genes  iPSCs  have  been Int. J. Mol. Sci. 2012, 13  3600 
 
 
shown  to  give  rise  to  functional  hepatocyte-like  cells  (iPSC-Heps)  [7,8].  Moreover,  hepatocytes 
generated  from  patient-specific  iPSCs  could  be  used  for  the  modeling  of  inherited  metabolic  
disorders [9]. Since  teratoma formation  from  pluripotent  stem  cells  is considered  an unacceptable 
obstacle for the application of stem cell therapy [10,11], our recent study demonstrated that iPSCs 
without  reprogramming  factors  c-Myc  (3-factors  iPSCs;  introduced  with  only  three  factors 
(Oct4/Sox2/Klf4)) can differentiate into hepatocyte-like cells (3-genes iPSC-Heps) and significantly 
improve thioacetamide (TAA)-induced acute liver injury with low incidence of tumorigenicity [12]. 
Although we provided evidence that 3-genes iPSCs may serve as a useful cell source for cell therapy 
against TAA-induced acute liver disease, most of this data was still premature and whether 3-genes 
iPSCs rescued an experimental model of AHF, induced by other chemicals, and improved hepatic 
encephalopathy remained uncertain. 
In the present study, we evaluated the hepatoprotective property of 3-genes iPSC transplantation in 
a  carbon  tetrachloride  (CCl4)-induced  AHF  model  in  mice.  Firstly,  we  demonstrated  that  3-genes 
iPSCs  possess  potential  to  differentiate  into  functional  iPSC-Heps  using  a  stepwise  protocol  as 
described  previously [12]. 3-genes iPSCs exhibited a  remarkable antioxidant activity that prevented 
CCl4-induced cell death in vitro. Next, we transplanted 3-genes iPSCs or 3-genes iPSC-Heps into 
CCl4-treated mice via an intraperitoneal route, and then investigated the hepatoprotective effect of  
3-genes iPSC transplantation in such a model. Our findings revealed that both 3-genes iPSCs and  
3-genes iPSC-Heps were mobilized to the injured livers and effectively reduced hepatic necrotic area 
and oxidative stress, improved hepatic functions, the survival rate, as well as impaired motor functions 
in mice pre-treated with CCl4. 
2. Results and Discussion 
2.1. In Vitro Differentiation of iPSCs into iPSC-Heps 
Recently, we demonstrated that 3-genes iPSCs are similar to both 4-genes iPSCs (iPSCs generated 
using  four  conventional  reprogramming  factors  Oct4/Sox2/Klf4/c-Myc)  and  ESCs  in  morphology, 
stem cell markers, and genomic traits [12]. In this study, 3-genes iPSCs were routinely cultured on 
inactivated MEF monolayers. Consistent with a previous report [12], 3-genes iPSCs are capable of 
forming colonies similar in appearance to mouse ESCs and 4-genes iPSCs (Figure 1A), and were 
stained positive for alkaline phosphate (Figure 1B). To further investigate the pluripotent property of 
3-genes iPSCs, we investigated the ability of 3-genes iPSCs for embryoid body (EB) formation and for 
tri-dermal differentiation. Using a different differentiation protocol, 3-genes iPSC-derived EBs could be 
differentiated  into  neuron-like  cells,  osteocyte-like  cells,  adipocyte-like  cells,  and  regular-beating 
cardiomyocyte-like  cells  (ectoderm  and  mesoderm;  data  not  shown).  To  evaluate  the  potential  of 
hepatic-specific differentiation (endoderm), 3-genes iPSC-derived EBs (EB; Figure 1C, upper left) 
were shifted to hepatic differentiation media, and these cells gradually exhibited more spread and 
cuboidal morphology over time and eventually differentiated into iPSC-derived hepatocyte-like cells 
(3-genes iPSC-Heps; Figure 1C; 28 days), as previous reported [12]. Moreover, the gene expressions 
of several hepatic-specific markers, including HNF-3, FP, ALB, TTR, AAT, TAT and HNF-4α 
were  largely  increased  over  time  and  reached  maximal  expression  at  post-differentiation  Day  28, Int. J. Mol. Sci. 2012, 13  3601 
 
 
indicating the maturation of these hepatocyte-like cells (Figure 1D; * P < 0.05 vs. undifferentiated 
iPSCs at Day 0). Along such a differentiation course, immunofluorescence analysis also confirmed the 
elevation of the protein content of hepatic-specific markers including HNF-3β, HNF-4α, FP and 
ALB (Figure 2A–D; P < 0.05 vs. undifferentiated iPSCs at Day 0). 
Figure 1. Differentiation of 3-genes iPSCs (induced pluripotent stem cells) into 3-genes 
iPSC-Heps. (A) 3-genes iPSCs are capable of forming colonies similar in appearance to 
mouse embryonic stem cells (ESCs) and 4-genes iPSCs; (B) Colonies of 3-genes iPSCs 
stained positive for alkaline phosphate; (C) Morphological changes of 3-genes iPSC-Heps 
during hepatocyte differentiation; (D) Recruitment of hepatocyte-specific genes, including 
HNF-3β,  FP,  ALB,  TTR,  AAT,  TAT,  and  HNF-4α  during  the  course  of  hepatocyte 
differentiation. In panels A, B and D, scale bar = 50 μm. In panel D, data shown here are 
the mean ±  SD of three independent experiments. * P < 0.05 vs. undifferentiated iPSCs at 
Day 0.  
 
To further examine whether these 3-genes iPSC-Heps also exhibited hepatic biological functions, 
we evaluated the hepatic biological functions in these cells, including LDL uptake, glycogen synthesis, 
and the enzyme activities of the liver enzyme cytochrome P450 3A4 and 1A2 (abbreviated as CYP450 
3A4 and CYP450 1A2, respectively; * P < 0.05 vs. undifferentiated iPSCs at Day 0). As shown in 
Figure 2, these 3-genes iPSC-Heps acquired ability for LDL uptake and glycogen synthesis (Figure 
2E,F, respectively; * P < 0.05 vs. undifferentiated iPSCs at Day 0), and also exhibited high activity of 
liver enzyme CYP450 3A4 and CYP450 1A2 (Figure 2G,H, respectively; * P < 0.05 vs. undifferentiated 
iPSCs at Day 0), along the course of hepatocyte-specific differentiation. Int. J. Mol. Sci. 2012, 13  3602 
 
 
Figure 2. Recruitment of hepatocyte-specific markers, biological functions and enzyme 
activities.  (A–D)  Detection  of  hepatocyte-specific  proteins  using  immunofluorescence. 
Immunostaining  imaging  (800× )  results  showed  several  hepatocyte-specific  markers, 
including HNF-3β, FP, ALB, and HNF-4α; (E) The uptake of Low-Density Lipoprotein 
(LDL) was measured by the incorporation rate of DiI-Ac-LDL and (F) the presence of 
stored glycogen was determined by PAS staining. The relative activities of (G) cytochrome 
P450 enzyme CYP3A4 and (H) CYP1A2 were analyzed by a commercial ELISA kit. Data 
shown here are the mean ±  SD of three independent experiments. In panels A–H; * P < 0.05 
vs. undifferentiated iPSCs at Day 0. 
 
2.2. 3-Genes iPSCs Possess an Antioxidant System Against CCl4-Induced Cell Death in Vitro 
A  previous  report  demonstrated  that  the  mechanism  of  CCl4-mediated  hepatotoxicity  involves 
reductive dechlorination of CCl4 to a trichloromethyl radical (
•CCl3) which subsequently precipitates 
membrane lipid peroxidation and hence liver damage [13]. Notably, iPSCs have been shown to possess 
anti-oxidant ability to suppress oxidative insult [14]. Prior to examining the hepatoprotective activity 
of 3-genes iPSC and/or 3-genes iPSC-Heps in CCl4-treated mice in vivo, we evaluated whether 3-genes 
iPSC and/or 3-genes iPSC-Heps were resistant to CCl4-induced cell death. CCl4 led to the death of 
MEFs in a dose-related manner, and the maximal cytotoxic effect was observed at 40 mmol/L CCl4 
(Figure 3A). Notably, the cytotoxic effect of CCl4 was partially blunted by 3-genes iPSC-Heps, and 
was fully prevented by 3-genes iPSCs (Figure 3A; * P < 0.05 vs. MEFs; # P < 0.05 vs. iPSC-Heps). 
We then compared the ability of reactive oxygen species (ROS) production among MEFs, 3-genes Int. J. Mol. Sci. 2012, 13  3603 
 
 
iPSC-Heps, and 3-genes iPSCs, in the presence or absence of CCl4. The intracellular ROS levels were 
the highest in MEFs, slightly lower in 3-genes iPSC-Heps and the lowest in 3-genes iPSCs (Figure 3B, 
P < 0.05 vs. MEFs without CCl4), indicating the prominent ROS scavenging activity in such cells. As 
expected, addition of CCl4 elicited a rapid increase in ROS production among MEFs, 3-genes iPSCs, 
and 3-genes iPSC-Heps (Figure 3B, P < 0.05 vs. MEFs with CCl4). Quantitative RT-PCR revealed that 
the highest expression of several antioxidant enzymes including Mn SOD, Cu/Zn SOD, catalase, GPX, 
and PRX in undifferentiated 3-genes iPSCs, as compared with 3-genes iPSC-Heps and MEFs (Figure 3C, * 
P < 0.05 vs. MEFs; # P < 0.05 vs. iPSC-Heps). In contrast, the expression of these enzymes was the 
lowest in MEFs (Figure 3C, * P < 0.05 vs. iPSCs and iPSC-Heps). These findings showed that the 
remarkable antioxidant activity of 3-genes iPSCs was associated with the high expression of several 
antioxidant enzymes. 
Figure 3. Effect of CCl4 administration on reactive oxygen species (ROS) production and 
cell survival in vitro. (A) Evaluation of CCl4-induced cytotoxicity and (B) ROS elevation 
in MEFs, 3-genes iPSCs, and 3-genes iPSC-Heps; (C) Comparison of the gene expression 
of  the  antioxidant  enzymes  in  MEFs,  3-genes  iPSCs,  and  3-genes  iPSC-Heps  using 
quantitative  RT-PCR.  Data  shown  here  are  the  mean  ±   SD  of  three  independent 
experiments. In panels A and C, * P < 0.05 vs. MEFs. # P < 0.05 vs. iPSC-Heps. In panel 
B, * P < 0.05 vs. MEFs with corresponding treatment. # P < 0.05 vs. iPSC-Heps with 
corresponding treatment. 
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2.3. Intraperitoneal Transplantation of 3-Genes iPSCs Reduced Hepatic Necrotic Area and  
Oxidative Stress 
AHF  is  a  severe  liver  disease  accompanied  by  high  mortality  and  hepatic  encephalopathy  that 
causes multiorgan  failure. Given that 3-genes  iPSCs  possess prominent antioxidant properties,  we 
subsequently  transplanted  3-genes  iPSCs,  3-genes  iPSC-Heps,  MEFs,  or  injected  PBS  via  an 
intraperitoneal  route,  and  then  assessed  the  therapeutic  potential  of  these  cells  in  CCl4-treated 
recipients. Firstly, we investigated the doses of  CCl4 required for induction of in vivo lethality in 
BALB/c  nude  mice  (Figure  4A).  We  found  that  CCl4  doses  greater  than  2.5  mL/kg  body  wt  by 
intraperitoneal injection elicited hyperacute injuries, leading to rapid death (10/10) within five days 
(Figure 4A). In the remaining experiments, we then used the dose 2.5 mL/kg body wt as the standard 
treatment (Figures 4–6). Twenty-four hours after cell transplantation at cell dose 2 ×  10
6 cells /kg body 
wt,  histological  examination  revealed  that  3-genes  iPSCs  exhibited  the most  pronounced  rescuing 
effect on hepatic necrotic areas rather than other cells and PBS (Figure 4B, * P < 0.05 vs. PBS or 
MEFs; # P < 0.05 vs. iPSC-Heps). The effect of MEF transplantation was not obvious at cell dose  
2 ×  10
5, 5 ×  10
5, 2 ×  10
6 and 5 ×  10
6 cells/kg body wt, whereas transplantation of either 3-genes iPSCs 
or 3-genes iPSC-Heps led to a remarkable reduction in necrotic area in CCl4-induced AHF at a cell 
dose greater than 5 ×  10
5 cells (Figure 4C, * P < 0.05 vs. MEFs at corresponding cell dose). Notably, 
the hepatoprotective effect of undifferentiated 3-genes iPSCs was dose-dependent and was higher than 
that of 3-genes iPSC-Heps (Figure 4C, # P < 0.05 vs. iPSC-Heps at corresponding cell dose). Along 
with  the  antioxidant  properties  of  3-genes  iPSCs  and  3-genes  iPSC-Heps  in  vitro  (Figure  3),  we 
subsequently examined whether transplantation of 3-genes iPSCs or 3-gene iPSC-Heps reduced the 
production of oxidative substances in vivo. Both MDA and nitrate/nitrite are indicative of oxidative 
damage.  CCl4  treatment  induced  the  production  of  MDA,  nitrate/nitrite  and  ROS  in  livers  from  all 
recipients (Figure 4D). The CCl4-induced production of MDA, nitrate/nitrite and ROS were not affected by 
MEF  transplantation.  Notably,  this  CCl4-induced  production  of  MDA,  nitrate/nitrite  and  ROS  was 
significantly lower in livers from recipients of 3-genes iPSCs and 3-genes iPSC-Heps, compared with 
PBS or MEFs (* P < 0.05 vs. PBS or MEFs). N-acetyl-cysteine (NAC) is known as an antioxidant that 
minimizes  oxidative  stress.  Addition  of  NAC  suppressed  the  CCl4-induced  elevation  of  MDA, 
nitrate/nitrite and ROS in recipients of PBS or MEFs the most and moderately in 3-genes iPSC-Heps 
(Figure 4D, # P < 0.05 vs. corresponding recipients with NAC treatment). NAC addition did not lead 
to further suppression of these low levels of MDA, nitrate/nitrite and ROS in CCl4-injured livers from 
3-genes iPSC recipients. Remarkably, the elevation of these oxidative substances was consistently 
maintained by 3-genes iPSCs at a low degree similar to those of MEF or 3-genes iPSC-Hep recipients 
treated with NAC, indicating the prominent antioxidant activity by 3-genes iPSCs. Compared with that 
of 3-genes iPSCs, the in vivo antioxidant activity of 3-genes iPSC-Heps was relatively lower. These 
findings demonstrated that 3-genes iPSCs and iPSC-Heps potentially suppressed ROS production and 
activated antioxidant enzymes in CCl4-injured livers.  Int. J. Mol. Sci. 2012, 13  3605 
 
 
Figure 4. Effect of intraperitoneal cell transplantation (PBS, mouse embryonic fibroblasts 
(MEFs),  iPSCs,  or  iPSC-Heps)  on  the  hepatic  pathology  in  CCl4-treated  mice.  
(A) Determination of the optimal dose for the induction of acute hepatic failure (AHF) by 
intraperitoneal administration of CCl4 into BALB/c nude mice. 2.5 mL/kg body CCl4 was 
used as the standard treatment; (B) Quantification of H&E-stain of CCl4-treated liver tissue 
from recipients; (C) Quantification of H&E-stained liver sections from CCl4-treated mice 
that received PBS injection, transplantation of MEFs, 3-genes iPSCs, or 3-genes iPSC-Heps 
at 2 ×  10
5, 5 ×  10
5, 2 ×  10
6, and 5 ×  10
6 cells /kg body wt; (D) Changes in ROS levels (left), 
MDA  content  (middle),  and  nitrite/nitrate  content  (right)  in  the  CCl4-injured  livers  of 
recipients  in  all  groups  with  and  without  N-acetyl-cysteine  (NAC)  pretreatment.  Data 
shown here are the mean ±  SD of six independent experiments. In panel A, * P < 0.05 vs. 
2.5 mL/kg body wt, # P < 0.05 vs. 2.0 mL/kg body wt. In panel B, * P < 0.05 vs. PBS or 
MEFs. # P < 0.05 vs. iPSC-Heps. In panel C, * P < 0.05 vs. PBS or MEFs at the same cell 
doses. # P < 0.05 vs. iPSC-Heps at the same cell doses. In panel D, * P < 0.05 vs. PBS or 
MEFs, # P < 0.05 vs. corresponding to recipient with NAC treatment. 
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Figure  5.  Effect of intraperitoneal cell transplantation (PBS, MEFs, 3-genes iPSCs, or  
3-genes iPSC-Heps) on hepatic pathology, survival rate and biochemical parameters in 
CCl4-treated recipients. (A) Hoechst-stained cell engraftment in the CCl4-injured liver from 
recipients  of  PBS,  MEFs,  iPSCs,  or  iPSC-Heps;  (B)  Representative  H  &  E  stain  of  
CCl4-treated liver tissue 24 h after receiving iPSCs, iPSC-Heps, MEFs or PBS treatment; 
(C) Intraperitoneal transplantation of 3-genes iPSCs or 3-genes iPSC-Heps rescued mice 
from lethal AHF. Data shown here are the mean ±  SD of six independent experiments. In 
panel, * P < 0.05 vs. PBS. In panel C, * P < 0.05 vs. PBS or MEFs. # P < 0.05 vs.  
iPSC-Heps.  
 
Figure 6. Effect of intraperitoneal cell transplantation on motor activity in CCl4-treated 
mice and tumorigenesis. CCl4-treated mice were injected with PBS or transplanted with  
3-genes iPSCs (2 ×  10
6 cells) via an intraperitoneal route to determine motor movements. 
Motor  activities  in  an  open  field  were  determined  by  using  the  Opto-Varimex  animal 
activity meter. Data are the mean ±  SD of six independent experiments. * P < 0.05 vs. PBS. 
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2.4. 3-Genes iPSCs and 3-Genes iPSC-Heps Rescued the Survival of CCl4-Induced AHF 
Our previous report revealed that intrasplenic transplantation led to event extent of engraftment 
among recipients of 3-genes iPSCs, 3-genes iPSC-Heps and MEFs [12]. In this study, we performed a 
tract-tracing study using immunofluorescence Hochest staining to trace the distribution of the cells, 
and we observed that MEF, 3-genes iPSCs, and 3-genes iPSC-Heps, with cell dose of 2 ×  10
6 cells by 
intraperitoneal transplantation, could also mobilize to the CCl4-damaged liver area to a similar extent 
(Figure 5A). Under this condition, 3-genes iPSCs/3-genes iPSC-Heps consistently reduced the hepatic 
necrotic area, and 3-genes iPSCs gave better efficacy than 3-genes iPSC-Heps at fixed dose of 2 ×  10
6 
cells (Figure 5B, a representative H & E stain of CCl4-treated liver tissue 24 h after receiving iPSCs,  
iPSC-Heps, MEFs or PBS treatment). CCl4 injection resulted in lethality in all of the PBS-treated 
recipients within 5 days, and MEF-treated recipients within 9 days (Figure 5C). However, sixty percent 
of mice were rescued at Day 12 by transplantation of 3-genes iPSC-Heps (6/10 mice, Figure 5C). 
Strikingly, transplantation of 3-genes iPSCs rescued ninety percent of mice (9/10 mice, Figure 5C) 
within the same experimental period.  
In PBS-treated mice, hepatic biochemical parameters including alanine aminotransferase (ALT), 
aspartate aminotransferase (AST) and total bilirubin (TBIL) gradually declined within 72 h, indicating 
tissue repair in the CCl4-injured liver (Table 1). 3-genes iPSC-Heps transplantation led to significant 
reduction in these biochemical parameters, as compared with PBS-treated or MEF recipients (Table 1; 
* P < 0.05 vs. MEFs). Identical to the protective effect on the hepatic necrotic area, the transplantation 
of  3-genes  iPSCs  led  to  an  even  more  pronounced  reduction  in  biochemical  parameters  than  for  
3-genes iPSC-Heps or MEFs (Table 1;  P < 0.05 vs. iPSC-Heps). 
Table 1. Effect of intraperitoneal transplantation of mouse embryonic fibroblasts (MEFs), 
iPSC-Heps, or induced pluripotent stem cells (iPSCs) on hepatic biochemical parameters in 
CCl4-treated recipients. 






BALB/c nude mice  11.1  3.5  55.2  10.8  0.45  0.4 
Recipient day 1 Post CCl4       
PBS  10125.5  680.5  6610.4  800.5  4.40  0.42 
MEFs  9912.2  620.0  5618.9  428.2  4.24  0.12 
iPSC-Heps  5084.5  432.8   2359.5  307.1   3.24  0.22  
iPSCs  2339.3  349.8 ,  1369.3  210.0 ,  2.28  0.20 , 
Recipient day 2 Post CCl4       
PBS  3135.1  451.4  2660.6  286.5  3.11  0.35 
MEFs  2679.8  424.7  2241.2  249.4  2.22  0.21 
iPSC-Heps  1807.6  305.5   1527.5  179.8   1.90  0.28  
iPSCs  865.6  171.2 ,  767.5  227.4 ,  1.29  0.15 , 
Recipient day 3 Post CCl4       
PBS  598.0  60.2  412.1  28.5  2.18  0.17 
MEFs  459.2 ±  56.1  362.8  8.5  1.32  0.12 
iPSC-Heps  139.1  10.9   104.5  8.8   1.22  0.18  
iPSCs  95.6  5.5 ,  60.3  6.7 ,  1.13  0.17 , 
Results were expressed as mean  SD from ten recipients. * P < 0.05 vs. MEFs;  P < 0.05 vs. iPSC-Heps. Int. J. Mol. Sci. 2012, 13  3608 
 
 
2.5. 3-Genes iPSCs Improved CCl4-Induced Hepatic Encephalopathy and Reduced Tumorigenesis 
Furthermore,  we  examined  whether  3-genes  iPSC  transplantation  could  improve  hepatic 
encephalopathy by assessing the motor activity of CCl4-treated mice after cell transplantation. Motor 
activity assay indicated  that, 72 h after CCl4 administration, the total  movements and ambulatory 
movements  were  significantly  increased  in  3-genes  iPSC  recipients  compared  to  mice  which  had 
received PBS injection only (Figure 6A, * P < 0.05 vs. PBS). These results demonstrated 3-genes iPSC 
treatment not only improved hepatic functions and animal survival, but also improved CCl4-induced 
hepatic encephalopathy. Furthermore, we performed an extended follow-up study for 4 months and 
found that recipients of 3-genes iPSCs and 3-genes iPSC-Heps survived, and no tumor formation was 
observed in either recipients. Severe tumor-like formation was found only in CCl4-treated recipients of 
4-genes iPSCs (with the oncogene c-Myc), which were used as the positive control of tumorigenicity 
in this extended study (Table 2). This raised the possibility that obviation of c-Myc in iPSCs and  
iPSC-Hep may substantially reduce the incidence of tumorigenesis after transplantation. 
Table 2. Incidence of tumor formation in recipients of 4-genes iPSCs, 3-genes iPSCs, or  
3-genes iPSC-Heps four months after transplantation. 
Group tumor formation  1 month  2 months  3 months  4 months 
4-genes iPSCs  0/6  1/6  2/6  3/6 
3-genes iPSCs  0/6  0/6  0/6  0/6 
4-genes iPSC-Heps  0/6  0/6  0/6  0/6 
2.6. Discussion 
The  only  curative  treatment  for  hepatic  failure  is  liver  transplantation  [1].  Unfortunately,  this 
treatment has several major limitations, thus it is urgent to develop an efficient alternative strategy for 
the  treatment  of  hepatic  failure  or  other  acute  hepatic  diseases.  Cell  therapy  which  has  minimal 
invasive procedures and fewer surgical complications has been considered as a potential therapeutic 
alternative for treatment of liver diseases [15–17]. Although ESCs and iPSCs have been implicated in 
cell therapy against liver diseases [3,7–9], teratoma formation from pluripotent stem cells is considered 
as  an  unacceptable  obstacle  for  stem  cell  therapy  [10,11].  Interestingly,  the  absence  of  the 
reprogramming factor c-Myc was reported to be associated with low incidence of tumorigenicity in our 
recent study [12] and the study reported elsewhere [18]. In the present study, our data also revealed the 
successful reprogramming of iPSCs from MEFs without introducing the factor c-Myc (Figure 1), the 
efficiency of hepatic specific differentiation into 3-genes iPSC-Heps with hepatic-specific genes and 
proteins (Figure 2), as well as mature biological functions such as LDL uptake and cytochrome p450 
activity  (Figure  2).  In  addition,  3-genes  iPSCs  exhibited  a  prominent  antioxidant  system  and  were 
resistant to CCl4-induced cell death  in vitro  (Figure  3). To ensure the  hepatoprotective property  of  
3-genes  iPSCs  and  3-genes  iPSC-Heps  in  vivo,  we  tested  the  hepatoprotective  effect  of  3-genes 
iPSCs/3-genes iPSC-Heps after cell transplantation into the mouse model of AHF, induced by the 
hepatotoxin CCl4. Transplantation of 3-genes iPSCs or 3-genes iPSC-Heps effectively rescued these 
CCl4-treated mice from lethal AHF, potentially reduced hepatic necrotic area and oxidative substances Int. J. Mol. Sci. 2012, 13  3609 
 
 
as well as improving liver functions and impaired motor functions (Figures 4–6, Table 1). These data 
further confirmed the therapeutic potential of 3-genes iPSCs/iPSC-Heps in AHF. 
CCl4  is  a  haloalkane  that  possesses  a  hepatotoxic  effect.  The  mechanism  of  CCl4-mediated 
hepatotoxicity involves reductive dechlorination of carbon tetrachloride (CCl4) to a trichloromethyl 
radical  (
•CCl3)  which  subsequently  precipitates  membrane  lipid  peroxidation  and  hence  causes  liver 
damage [13]. TAA, a thiono-sulfur containing compound, has been used as a fungicide, organic solvent, 
and  accelerator  in  the  vulcanization  of  rubber,  as  well  as  a  stabilizer  of  motor  oil  [19].  TAA 
administration can lead to accumulation of the reactive oxygen species (ROS) and lipid peroxides, 
liver cell damage, fibrosis and/or cirrhosis [20–22]. In the livers, the nuclear factor kappa B (NFB) is 
consequently  activated  by  TAA  administration,  followed  by  elevation  of  the  expression  of 
proinflammatory cytokines [23,24]. Our previous study indicated that engrafted 3-genes iPSCs and  
3-genes iPSC-Heps exhibited remarkable ROS scavenging activity in the damaged areas of TAA-injured 
livers, and protected the liver from TAA-elicited hepatotoxicity [12]. Moriya et al. reported that the 
graft of undifferentiated ESCs can develop into hepatocyte-like cells with appropriate integration into 
the CCl4-injured liver and subsequent improved liver damage [25]. Kuo et al. reported that cell therapy 
using mesenchymal stem cells rescued hepatic failure in CCl4-treated mice, probably due to reduction 
of oxidative stress and accelerated repopulation of hepatocyte after liver damage [26]. In the present 
study, our data showed that both 3-genes iPSCs and 3-genes iPSC-Heps possess several antioxidant 
enzymes  that  protect  these  cells  from  CCl4-induced  death.  These  cells  also  showed  marked 
hepatoprotective  efficacy  on  the  experimental  AHF  model  induced  by  CCl4  administration.  The 
hepatoprotective activity of 3-genes iPSCs/3-genes iPSC-Heps remained uncertain in CCl4-challenged 
livers. Although the free radical species generated by TAA and CCl4 were not fully identical, it is 
likely that reduction of in vivo oxidative stress serves as one of the underlying mechanisms mediating 
the hepatoprotective effect of 3-genes iPSCs/iPSC-Heps. Hepatic functions were gradually recovered 
in both MEF and PBS-treated recipients, indicating tissue repair at injury sites (Table 1). Importantly, 
transplantation of either 3-genes iPSCs or 3-genes iPSC-Heps further improved hepatic functions by 
facilitating tissue repair at injury sites (Table 1). These data suggested that 3-genes iPSCs/3-genes 
iPSC-Heps possess a paracrine effect that may stimulate hepatocyte proliferation, and this property 
may  also  partially  mediate  the  hepatoprotective  effect  of  3-genes  iPSCs/3-genes  iPSC-Heps  in  
CCl4-treated mice. 
It was extensively demonstrated that stem cells can mobilize into circulation in response to injury 
signals and contribute to tissue repair at injury sites [26–28]. Hence, the route of cell transplantation is 
critical for the hepatoprotective activity of 3-genes iPSCs/3-genes iPSC-Heps. Portal vein recruited 
blood from the gastrointestinal tract and spleen to the liver. Our recent study demonstrated intravenous 
transplantation of an equal amount of cells led to lower engraftment of 3-genes iPSC-Heps, compared 
with that of 3-genes iPSCs. Nevertheless, intrasplenic transplantation led to an even extent of hepatic  
cell engraftment [12]. The discrepancy in the efficacy of intravenous transplantation and intrasplenic 
transplantation  was  attributed  to  the  lower  mobilization  of  differentiated  cells  from  the  systemic 
circulation to the injured site, compared with that of undifferentiated cells  [12,26]. Intraperitoneal 
injection is the injection of a substance, preferably in a large amount, into the peritoneum [29]. Lukas et 
al. demonstrated that compounds administered intraperitoneally are absorbed primarily through the 
portal circulation and must pass thorough the liver before reaching other organs [29]. In the present Int. J. Mol. Sci. 2012, 13  3610 
 
 
study,  intraperitoneal  transplantation  also  led  to  an  even  extent  of  hepatic  engraftment  between 
recipients  of  3-genes  iPSCs,  3-genes  iPSC-Heps,  and  MEFs,  consistent  with  Lukas  et  al.’s 
observations addressing the consequence of intraperitoneal administration. These results indicated that 
the intraperitoneal approach is an ideal route for cell transplantation and could be used for iPSC-based 
therapy in subsequent researches. 
Hepatic encephalopathy, the occurrence of confusion, altered level of consciousness and coma, is 
one of the complications associated with fulminant hepatic failure [1]. Our findings revealed that 3-genes 
iPSC-based  therapy  not  only  improved  hepatic  functions  and  animal  survival,  but  also  improved  
CCl4-induced  hepatic  encephalopathy  (Figure  6A).  The  pathogenesis  of  hepatic  encephalopathy  is 
quite  different  and  the  exact  mechanisms  leading  to  this  functional  disturbance  are  not  clearly 
understood [30]. There is accumulating evidence that a number of pathophysiological mechanisms 
exist or co-exist, such as elevation of ammonia levels, changes in GABA-receptor complex, changes in 
serotonin metabolism, storage or release, etc. [30]. To our knowledge, this is the first report showing 
that 3-genes  iPSC transplantation improved both AHF and hepatic  encephalopathy. This  potential 
therapeutic  effect  of  3-genes  iPSCs  against  hepatic  encephalopathy  might  be  secondary  to  the 
normalization of hepatic functions such as the ammonium metabolism. However, future investigations 
are  necessary  to  elucidate  the  precise  mechanism  of  the  iPSC-mediated  effect  on  hepatic 
encephalopathy. 
3. Materials and Methods 
3.1. 3-Genes iPSC Culture and in Vitro Hepatic Differentiation 
Murine iPSCs were generated from mouse embryonic fibroblasts (MEFs) derived from 13.5-day-old 
embryos  of  C57/B6  mice.  The  iPSCs  were  reprogrammed  by  the  transduction  of  retroviral  
vectors  encoding  three  transcription  factors  (Oct4/Sox2/Klf4),  as  described  previously  with  some 
modifications  [11].  Briefly,  undifferentiated  iPSCs  were  routinely  cultured  and  expanded  on 
mitotically-inactivated MEFs (50,000 cells/cm
2) in six-well culture plates (BD Technology) in the 
presence of 0.3% leukemia inhibitory factor in an iPSC medium consisting of Dulbecco’s Modified 
Eagle’s  Medium  (DMEM;  Sigma)  supplemented  with  15%  fetal  bovine  serum  (FBS;  Invitrogen),  
100  mM  minimal  essential  medium  (MEM)  nonessential  amino  acids  (Sigma),  0.55  mM  
2-mercaptoethanol  (Gibco),  and  antibiotics  (Invitrogen).  The  mouse  iPSCs  were  transfected  with  
pCX-EGFP  to  constitutively  express  green  fluorescence  and  were  maintained  and  differentiated  
in vitro as described previously [31]. Every three to four days, colonies were detached with 0.2% 
collagenase IV (Invitrogen), dissociated into single cells with 0.025% trypsin (Sigma-Aldrich) and 
0.1% chicken serum (Invitrogen) in PBS, and replated onto MEFs. For embryoid body (EB) formation, 
iPSCs  were  dissociated  into  a  single  cell  suspension  by  0.25%  trypsin-EDTA  and  plated  onto  
non-adherent  culture  dishes  in  DMEM  with  15%  FBS,  100  mM  MEM  nonessential  amino  acids,  
0.55 mM 2-mercaptoethanol, and antibiotics at a density of 2 ×  10
6 cells/100 mm plate. After 4 days in 
floating culture, EBs were transferred onto gelatin-coated plates and maintained in the same medium 
for 24 h. EBs were then assigned for in vitro hepatocyte differentiation by using a two-step procedure 
as previously described, with some modifications [32]. For endoderm induction, iPSCs were incubated Int. J. Mol. Sci. 2012, 13  3611 
 
 
for 24 h in RPMI 1640 medium (Invitrogen/Gibco, Rockville, MD, USA), supplemented with 100 ng/mL 
Activin  A  (Peprotech).  On  the  following  2  days,  0.1  and  then  1%  insulin-transferrin-selenium 
(Invitrogen/Gibco) was added to this medium. Following Activin A treatment, the differentiated iPSCs 
were cultured in Hepatocyte Culture Medium (HCM) (Cambrex, Baltimore, MD, USA) containing  
30 ng/mL FGF4 for 4 days. Then, the differentiated cells were incubated in HCM containing 20 ng/mL 
HGF for 6 days, in HCM containing 10 ng/mL oncostatin-M (R&D, Minneapolis, MN, USA) plus  
0.1 M dexamethasone (Sigma-Aldrich) for 5 days. 
3.2. Cellular Uptake Assay of Low-Density Lipoprotein (LDL) 
The uptake capability of 1,1’-dioctadecyl-3,3,3’,3’-tetramethylindocarbocyanine perchlorate conjugated 
to  acetylated-LDL  (DiI-Ac-LDL;  AbD  Serotec)  of  iPSCs  and  differentiated  cells  was  determined  
by fluorescent microscopy. Cells were incubated with 20  g/mL DiI-AC-LDL at 37 ° C for 24 h. 
Incorporation of DiI-Ac-LDL into cells was visualized by fluorescence microscopy. 
3.3. Periodic Acid-Schiff (PAS) Stain for Glycogen 
Cells were ﬁxed in 4% paraformaldehyde, and then permeabilized with 0.1% Triton X-100 for  
10 min. Samples were then oxidized in 1% periodic acid for 5 min, rinsed 3 times in deionized water 
(dH2O), treated with Schiff’s reagent for 15 min, and rinsed in dH2O for 5 to 10 min. Samples were 
counterstained with Mayer’s hematoxylin for 1 min and then rinsed in dH2O. Samples were observed 
under the light microscope. 
3.4. ELISA Analysis 
For the determination of the enzyme activities of the liver enzyme cytochrome P450 3A4 and 1A2, 
cells were collected and properly prepared for analysis of the activities of liver enzyme cytochrome 
P450 3A4 and 1A2 by a commercialized cytokine assay kit (Promega) according the manufacture’s 
instructions. The activity of individual cytochrome P450 enzymes was quantified by densitometry and 
expressed as fold change relative to undifferentiated iPSCs. 
3.5. Real-Time Reverse Transcription-Polymerase Chain Reaction 
Real-time RT-PCR was performed as previously described [33]. For real-time RT-PCR analysis, 
the total RNA of cells was extracted by using the RNAeasy kit (Qiagen, Valencia, CA, USA). Briefly, 
the total RNA (1 mg) of each sample was reversely transcribed in 20 mL using 0.5 mg of oligo dT and  
200 U Superscript II RT (Invitrogen, Carlsbad, CA, USA). The amplification was carried out in a total 
volume of 20 mL containing 0.5 mM of each primer, 4 mM MgCl2, 2 mL LightCycler FastStart DNA 
Master SYBR green I (Roche Diagnostics, Pleasanton, CA) and 2 mL of 1:10 diluted cDNA. The 
quantification  of  the  unknown  samples  was  performed  by  LightCycler  Relative  Quantification 
Software, version 3.3 (Roche Diagnostics). In each experiment, the GAPDH housekeeping gene was 
amplified as a reference standard. PCR reactions were prepared in duplicate and heated to 95 ° C for  
10 min followed by 40 cycles of denaturation at 95 ° C for 10 s, annealing at 55 ° C for 5 s, and 
extension at 72 ° C for 20 s. All PCR reactions were performed in duplicate. Standard curves (cycle Int. J. Mol. Sci. 2012, 13  3612 
 
 
threshold  values  versus  template  concentration)  were  prepared  for  each  target  gene  and  for  the 
endogenous reference (GAPDH) in each sample. The expression level of liver specific genes  was 
evaluated as the ratio of its mRNA to that of β-actin. 
3.6. Immunofluorescence Staining  
An  avidin-biotin  complex-based  method  was  used  for  immunohistochemical  staining  of 
differentiated iPSCs. Following washes with 3% hydrogen peroxide, sodium azide and antigenicities 
were retrieved using a microwave. Each slide was then treated with antibodies for HNF-3β (Chemicon 
International, Temecula, CA), Albumin (Chemicon International, Temecula, CA, USA), AFP (Upstate 
Biotechnology,  Waltham,  MA,  USA).  Immunoreactive  signals  were  detected  with  a  mixture  of 
biotinylated rabbit anti-mouse IgG and Fluoresave (Calbiochem, La Jolla, CA, USA) and a confocal 
microscope (Olympus, FV300). The mean numbers of immunoreactive cells of per 100 cells (%) were 
used in statistical analysis. 
3.7. Cell Viability Assay 
iPSCs were seeded on 24-well plates at a density of 2 ×  10
4 cells/well in medium and submitted to a 
methyl  thiazol  tetrazolium  assay  (MTT  assay;  Sigma-Aldrich).  iPS  cells  were  incubated  with  
0.25  mg/mL  MTT  for  4  h  at  37  ° C,  and  the  reaction  was  terminated  by  the  addition  of  100% 
isopropanol (16). The amount of MTT formazon product was determined by using a microplate reader, 
and absorbance was measured at 560 nm (SpectraMax 250, Molecular Devices, Sunnyvale, CA, USA). 
3.8. Cell-Labeling Protocol 
Hoechst 33258 (Sigma) is widely used to label DNA, and these fluorescent stains are commonly 
used to visualize nuclei. In serum-free culture medium, 1 ×  10
6 human iPSCs were incubated with 
Hoechst 33258 (10 M) for 60 min at 37 ° C, and then centrifuged at 1500 rpm for 5 min at 37 ° C. 
Later, the supernatant was removed and the cells gently re-suspended in PBS. Hoechst-labeled-iPSCs 
were  directly  applied  to  animal  experiments.  Fluorescence-labeled  cells  were  observed  under  a 
fluorescent microscope. Each slide was evaluated by two separate investigators in a blinded manner. 
To quantify the scattered density of the incorporated cells, a total of 10 liver sections of each sample 
were counted on each slide at 100×  magnification. The scattered density was expressed as cell count 
per liver section field in mean ±  SD. 
3.9. Animal Model of Liver Injury 
Male BALB/c nude mice, 8 weeks old and weighing 25–30 g, were used for our experiments. 
Fulminant hepatic failure was induced by intraperitoneal injection of CCl4 (2.5 mL/kg body weight;  
1:4 v/v in mineral oil). Four hours after CCl4 administration, mice were injected with MEFs, iPSCs or 
iPSC-Heps at 4 different doses: 5 ×  10
6 cells/kg body wt (Group I), 2 ×  10
6 cells/ kg body wt (Group II), 
5 ×  10
5 cells/kg body wt (Group III), or 2 ×  10
5 cells/kg body wt (Group IV), via intraperitoneal 
injection. In order to observe prolonged hepatic damage, measurement of survival and collection of 
blood samples were performed at 24, 48, or 72 h after the administration of CCl4 in recipients of PBS, Int. J. Mol. Sci. 2012, 13  3613 
 
 
MEFs, iPSCs, or iPSC-Heps. All mice were caged at 24 ° C with a 12-h light-dark cycle and allowed 
free access to water and food. This study was approved by Taipei Veterans General Hospital Animal 
Committee,  and  the  principles  of  Laboratory  Animal  Care  were  followed.  To  explore  the  role  of  
CCl4-elicited  reactive  oxygen  species  (ROS)  production  and  evaluate  the  antioxidant  property  of  
N-acetylcysteine (NAC), mice were treated chronically with NAC at a dose of 500 mg/kg/day in the 
drinking water, as previously described [34]. 
3.10. Histological Quantification of Liver Injury 
The harvested livers were fixed, embedded in paraffin and sectioned for evaluation of the degree of 
liver injury. The livers were fixed in 4% paraformaldehyde, dehydrated using graded ethanol, and then 
embedded in paraffin. The paraffin blocks were sectioned and stained with hematoxylin and eosin (HE) 
using standard histological techniques. CCl4 injection resulted in liver parenchyma damage mainly 
around the central veins. The necrotic area in an injured liver can be distinguished from normal liver 
tissue by the brighter color and the presence of inflammatory cell infiltrates. The liver sections were 
examined and photo-taken under microscope at 10×  magnification. The necrotic areas of the injured 
liver  were  determined  by  measuring  five  independent  fields  per  liver  using  a  computerized 
morphometry system. The percentage of relative necrotic area (%) was calculated  by dividing the 
necrotic area by total observed area. 
3.11. Liver Functional Tests 
Biochemical  parameters  were  measured  using  standard  clinical  methods.  After  anesthesia  by 
ketamine (10 mg/100 g), intracardiac aspiration of blood was performed. A 0.8–0.9 mL blood sample 
was collected from the heart in a pyrogen-free syringe containing ~75 units of heparin sodium, then 
placed  in  an  ice  bath  and  transported  immediately  to  the  laboratory.  Serum  biochemistry  tests, 
including alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin, were 
measured by Vitro DT chemistry system (Johnson & Johnson). 
3.12. Determination of Intracellular Reactive Oxygen Species (ROS) Production 
The  measurement  of  intracellular  reactive  oxygen  species  (ROS)  production  by  the  probe  
2’,7’-dichlorofluorescein  diacetate  (DCFH-DA;  Molecular  Probes,  Eugene,  OR,  USA)  has  been 
mentioned  previously  [35].  In  brief,  cells  were  incubated  with  5  μmol/L  DCFH-DA  in  a  culture 
medium for 30 min at 37 ° C, followed by washing with PBS and flow cytometry analysis. 
3.13. Malondialdehyde Assay 
Malondialdehyde (MDA) in liver tissue was assayed using a commercial kit for thiobarbituric acid 
reactive  substances  (TBARS;  Cayman  Chemical,  Ann  Arbor,  MI).  Absorbance  at  530  nm  was 
determined  using  an  enzyme-linked  immunosorbent  assay  (ELISA)  reader  (Bio-Rad  Laboratories, 
Hercules, CA, USA). 
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3.14. Nitrate/Nitrite Concentration 
Nitrite and nitrate are the primary oxidation products of NO subsequent to reaction with oxygen and, 
therefore, the nitrite/nitrate concentration was used as an indicator of NO synthesis. Nitrite/nitrate 
levels in mouse tissue were measured after enzymatic conversion of nitrate to nitrite using nitrate 
reductase.  Subsequently,  total  nitrite  in  liver  tissue  was  assayed  by  adding  100  L  Griess  reagent 
(0.05% naphthalethylenediamine dihydrochloride and 0.5% sulphanilamide in 2.5% phosphoric acid) 
to each sample. The optical density at 550 nm (OD550) was measured and the total nitrite/nitrate 
concentration for each sample was calculated by comparison of the OD550 of a standard solution of 
sodium nitrate prepared in saline. 
3.15. Measurement of Motor Activity 
Motor activities in an open field were determined by using the Opto-Varimex animal activity meter 
(Columbus  Instruments  Inc.)  [36,37].  The  Opto-Varimex  activity  sensors  utilize  high-intensity, 
modulated infrared light beams to detect animal motion. Animals were housed in transparent cages  
(17 inches ×  17 inches ×  8 inches) through which 30 infrared beams pass in the horizontal plane, 15 on 
each  axis.  This  device  differentiates  non-ambulatory  movements  (scratching,  gnawing)  from 
ambulation on the basis of consecutive interruption of the infrared monitoring beams. An additional 
row of infrared beams in the horizontal plane (15 on each axis) about 10 cm above the floor was used 
to count the vertical movements. During the activity measurements, animals have no access to food or 
chow. All studies were performed under strictly standardized conditions in the dark room for 30 min. 
The counting numbers of the total movements, ambulatory movements, and vertical movements were 
separately recorded to reflect the motor activities of rats with fulminant hepatic failure. The motor 
activities were defined as zero in dead mice. 
3.16. Statistical Analysis 
Results  were  expressed  as  mean  ±   S.D. Statistical  analyses  were performed by using unpaired 
Student’s t-tests, and the survival rate analysis using log-rank test. Results were considered statistically 
significant at P < 0.05. 
4. Conclusions  
In  conclusion,  this  report  demonstrated  that  iPSCs  and  iPSC-Heps  expressing  only  
Oct-4/Sox2/Klf-4  effectively  rescued  CCl4-induced  AHF,  via  an  intraperitoneal  route  of  cell 
transplantation. The hepatoprotective effect of  3-genes iPSCs/iPSC-Heps may be partially through 
their antioxidant activity and/or facilitating the hepatic tissue repair in a paracrine manner. Considering 
the  prominent  hepatoprotective  effect  of  the  3-genes  iPSCs/iPSC-Heps  in  different  models  of 
fulminant  hepatic  failure,  these  3-genes  iPSCs/3-genes  iPSC-Heps  may  serve  as  an  alternative  
against AHF. 
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